Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.

A Decade of SG&A: Amgen Inc. vs. Exelixis, Inc.

In the competitive landscape of biotechnology, operational efficiency is key. Over the past decade, Amgen Inc. and Exelixis, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Amgen, a giant in the industry, consistently reported SG&A expenses averaging around $5.3 billion annually, peaking at $6.2 billion in 2023. This reflects a steady growth of approximately 31% from 2014. In contrast, Exelixis, a smaller player, showed a more dynamic increase, with SG&A expenses surging by over 900% from $50 million in 2014 to $543 million in 2023. This stark difference highlights the varied approaches to scaling operations and market presence. As the biotech sector evolves, these financial strategies will play a crucial role in shaping the future trajectories of these companies.